Mycophenolate mofetil and curcumin provide comparable therapeutic benefit in experimental chronic kidney disease: role of Nrf2-Keap1 and renal dopamine pathways
- 4 May 2016
- journal article
- research article
- Published by Taylor & Francis in Free Radical Research
- Vol. 50 (7) , 781-792
Abstract
Increased oxidative stress and inflammation have an important role in the pathophysiology of chronic kidney disease (CKD). On the other hand, more affordable therapeutic alternatives for treating this disease are urgently needed. Therefore, we compared the therapeutic efficacy of curcumin and mycophenolate mofetil (MMF) in 5/6 nephrectomy (5/6 Nx) model of CKD. Also, we evaluated whether both compounds provide benefit through the preservation of similar antioxidant mechanisms. Four groups of male Wistar were studied over a period of 4 wk. Control sham group (n= 12), 5/6 Nx (n = 12), 5/6 Nx + MMF (30 mg/k BW/day, n = 11) and 5/6 Nx + Curcumin (120 mg/k BW/day, n = 12). Renal function and markers of oxidative stress and inflammation were evaluated. Also Nrf2-Keap1 and renal dopamine, antioxidant pathways were assessed. 5/6 Nx induced an altered renal autoregulation response, proteinuria, and hypertension; these effects were in association with increased oxidative stress, endothelial dysfunction and renal inflammation. The mechanisms associated with these alterations included a reduced nuclear translocation of Nrf2 and hyperphosphorylation of dopamine D1 receptor with a concurrent overactivation of renal NADPH oxidase. Treatments with MMF and curcumin provided equivalent therapeutic efficacy as both prevented functional renal alterations as well as preserved antioxidant capacity and avoided renal inflammatory infiltration. Moreover, both treatments preserved Nrf2-Keap1 and renal dopamine antioxidant pathways. In summary, therapeutic strategies aimed to preserve renal antioxidant pathways can help to retard the progression of CKD.Keywords
Funding Information
- Secretaría de Ciencia, Humanidades, Tecnología e Innovación (133232, 167949 and 155604)
This publication has 42 references indexed in Scilit:
- Dose-dependent deleterious and salutary actions of the Nrf2 inducer dh404 in chronic kidney diseaseFree Radical Biology and Medicine, 2015
- Natural Nrf2 activators in diabetesClinica Chimica Acta, 2015
- Efficacy and safety of mycophenolate mofetil treatment in IgA nephropathy: a systematic reviewBMC Nephrology, 2014
- Effect of Redox Modulating NRF2 Activators on Chronic Kidney DiseaseMolecules, 2014
- Renal Dopamine Receptors, Oxidative Stress, and HypertensionInternational Journal of Molecular Sciences, 2013
- Renal microvascular dysfunction, hypertension and CKD progressionCurrent Opinion in Nephrology and Hypertension, 2013
- A decade of mycophenolate mofetil for lupus nephritis: is the glass half-empty or half-full?Annals of the Rheumatic Diseases, 2010
- Chronic kidney disease: a public health priority and harbinger of premature cardiovascular diseaseJournal of Internal Medicine, 2010
- Mycophenolate mofetil prevents arteriolopathy and renal injury in subtotal ablation despite persistent hypertensionKidney International, 2003
- Mycophenolate mofetil prevents the progressive renal failure induced by 5/6 renal ablation in ratsKidney International, 1999